Li Cai

Li Cai is currently the Vice Chairman at Hangzhou Kangji Medical Instrument Co., Ltd., the Managing Director at TPG Capital Asia Inc, the Director at Novotech (Australia) Pty Ltd., the Director at Biosuntek Laboratory Co. Ltd., the Director at Zhejiang Choisun Tea Development Co. Ltd., the Non-Executive Director at Kangji Medical Holdings Ltd., the Director at Opc Co. Holdings Cayman Islands Ltd., the Director at Opc Intermediate Holding Co. Cayman Islands Ltd., the Director at Ppc Kk Japan Ltd., the Director at Apluscro Pte Ltd., the Director at Ppc Korea Ltd., the Director at Ppc China Corp.
Ltd., the Director at Ppc China Clinical Research Corp.
Ltd., the Director at Jiasheng Shanghai Pharmaceutical Consulting Co. Ltd., the Director at Aplus Pharmaceutical Consulting Shanghai Co. Ltd., the Director at Bailixing Xiamen Equity Investment Co. Ltd., the Director at Acrostar Pharmaservices Corp., the Director at Acrostar Site Management Co. Ltd., the Director at Novotech Holdings Pty Ltd., the Director at Novotech Aus Holdco Pty Ltd., the Non-Executive Director at Novotech Health Holdings Ltd., the Non-Executive Director at Dingdang Health Technology Group Ltd., the Director at Ppc Holding Co., the Non-Executive Director at Chongho Bridge Ltd., the Director at Novotech Laboratory Services Shanghai Co. Ltd., the Principal at TPG Capital-China Ltd., and a Member-Supervisory Board at Shanghai Deyu Deqi Enterprise Management Consulting Co. Ltd.
Ms. Cai previously worked as a Non-Executive Director at Zhaoke Ophthalmology Ltd.
from 2020 to 2023, a Non-Executive Director at Shanghai Bio-Heart Biological Technology Co., Ltd.
from 2020 to 2022, and an Investment Associate at Hao Capital Co. Ltd.
from 2009 to 2011.
Ms. Cai completed their undergraduate degree at Yale University in 2017.